Anemia in India
Get Anemia at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Anemia in UAE
Anemia at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Anaemia — whether iron-deficiency, vitamin B12-deficiency, haemolytic, or aplastic in origin — affects over 1.6 billion people globally and demands precise haematological evaluation to determine the safest, most effective treatment pathway. India and the UAE host internationally accredited haematology centres staffed by specialists trained at leading global institutions, offering intravenous iron infusion protocols (ferric carboxymaltose, iron sucrose, low-molecular-weight iron dextran), high-dose intramuscular or oral B12 (cobalamin) repletion, erythropoiesis-stimulating agents (ESAs), and advanced workups including bone marrow biopsy with flow cytometry for complex or refractory anaemia. With clinical success rates exceeding 92% for first-line iron and B12 correction protocols and GAF Healthcare's end-to-end coordination — from specialist matching to visa facilitation — international patients access world-class haematology care at a fraction of Western costs.
Hospital Stay: 0–3 days (day-care for infusions; 3–7 days for complex/aplastic anaemia workup or bone marrow procedures) • Total Stay in Country (Fit-to-Fly): 1–3 weeks (1 week post-infusion series for uncomplicated iron/B12 deficiency; 3–4 weeks for bone marrow biopsy or complex haematological investigation) • Success Rate: 92–97% (haemoglobin normalisation within 8–12 weeks for iron-deficiency and B12-deficiency anaemia; outcomes vary for aplastic or haemolytic subtypes)
What Is It?
Anaemia is defined as a reduction in circulating haemoglobin below 13 g/dL in adult males or 12 g/dL in adult females, impairing oxygen-carrying capacity and triggering compensatory tachycardia, increased cardiac output, and progressive tissue hypoxia. The WHO classifies anaemia by severity — mild (Hb 10–11.9 g/dL), moderate (Hb 7–9.9 g/dL), and severe (Hb <7 g/dL) — each requiring escalating therapeutic urgency. Physiologically, chronic iron deficiency depletes ferritin stores, suppresses transferrin saturation, and ultimately impairs haem synthesis in erythroid precursors within the bone marrow; untreated, this leads to symptomatic fatigue, cognitive impairment, impaired immune function, and in severe cases, high-output cardiac failure.
The aetiology of anaemia is broad and critically determines treatment: iron-deficiency anaemia (IDA) — the most prevalent subtype globally — requires iron repletion either orally or intravenously depending on severity, gastrointestinal absorption status, and comorbidities; megaloblastic anaemia from B12 (cobalamin) or folate deficiency requires targeted vitamin repletion and investigation of pernicious anaemia via intrinsic factor antibody testing; haemolytic anaemias (autoimmune, hereditary spherocytosis, G6PD deficiency, sickle cell disease, thalassaemia) require immunosuppression, disease-modifying therapies, or in selected cases, splenectomy or haematopoietic stem cell transplantation (HSCT); and aplastic anaemia — the most severe form — demands bone marrow evaluation followed by immunosuppressive therapy (anti-thymocyte globulin, cyclosporine) or allogenic bone marrow transplant.
The international standard of care begins with a structured haematological workup including a complete blood count (CBC) with peripheral blood smear, reticulocyte count, serum ferritin, serum iron, total iron-binding capacity (TIBC), transferrin saturation, serum B12, serum folate, LDH, direct Coombs test, and — where indicated — bone marrow aspirate and biopsy with flow cytometry, cytogenetics, and FISH panel. Leading haematology centres in India (Apollo, Fortis, Tata Memorial, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai, American Hospital Dubai) follow BCSH (British Committee for Standards in Haematology), ASH (American Society of Hematology), and ESMO guidelines for all anaemia subtypes, ensuring internationally benchmarked diagnostic and therapeutic precision.
Candidates
• ELIGIBLE PATIENTS (Iron-Deficiency Anaemia):
• Adults and children with confirmed IDA (serum ferritin <30 ng/mL, transferrin saturation <20%) who have failed or are intolerant to oral iron supplementation
• Patients with inflammatory bowel disease, post-bariatric surgery malabsorption, chronic kidney disease (CKD), or active GI bleeding causing ongoing iron losses
• Pre-operative patients with Hb <10 g/dL requiring optimisation before elective surgery (patient blood management protocols)
• Patients requiring rapid haemoglobin correction (Hb <8 g/dL with cardiopulmonary symptoms) where oral iron is too slow
• ELIGIBLE PATIENTS (B12 / Folate Deficiency Megaloblastic Anaemia):
• Adults with confirmed B12 <200 pg/mL or folate <4 ng/mL presenting with macrocytic anaemia (MCV >100 fL) ± neurological symptoms (subacute combined degeneration of spinal cord)
• Patients with pernicious anaemia (confirmed by positive intrinsic factor antibody or anti-parietal cell antibody) requiring lifelong intramuscular cyanocobalamin or hydroxocobalamin
• Strict vegans or vegetarians with dietary B12 deficiency
• Post-gastrectomy patients with absent intrinsic factor
• ELIGIBLE PATIENTS (Complex / Haemolytic / Aplastic Anaemia):
• Patients with unexplained anaemia unresponsive to iron/B12, requiring bone marrow biopsy to exclude myelodysplastic syndrome (MDS), aplastic anaemia, leukaemia, or lymphoma
• Patients with haemolytic anaemia (positive direct Coombs test, elevated LDH, low haptoglobin) requiring immunosuppressive workup
• Thalassaemia major or sickle cell disease patients requiring transfusion optimisation or HSCT evaluation
• Patients with aplastic anaemia (bone marrow cellularity <25%) eligible for immunosuppressive therapy (ATG + cyclosporine) or allogeneic stem cell transplantation
• REQUIRED DIAGNOSTIC TESTS (PRE-TREATMENT):
• Complete Blood Count (CBC) with differential and peripheral blood smear morphology
• Serum ferritin, serum iron, TIBC, transferrin saturation
• Serum vitamin B12, serum folate, methylmalonic acid (MMA), homocysteine (for B12 deficiency confirmation)
• Reticulocyte count and reticulocyte production index (RPI)
• LDH, haptoglobin, direct and indirect Coombs test (haemolysis screen)
• Intrinsic factor antibody, anti-parietal cell antibody (if pernicious anaemia suspected)
• Renal function panel (eGFR, creatinine) — critical for ESA dosing in CKD-related anaemia
• Bone marrow aspirate + trephine biopsy with flow cytometry, cytogenetics (karyotyping), and FISH panel (for aplastic anaemia, MDS, or haematological malignancy workup)
• HLA typing (if allogeneic bone marrow transplant is under consideration)
• Thyroid function tests (TFT), liver function tests (LFT) — to exclude secondary causes
• Upper GI endoscopy / colonoscopy (where GI blood loss is the suspected aetiology)
• CONTRAINDICATIONS / RELATIVE CAUTIONS:
• IV iron infusion is contraindicated in active systemic bacterial infection (risk of iron-fuelled bacterial proliferation) and known hypersensitivity to iron preparations; caution required in first-trimester pregnancy
• ESAs (epoetin alfa, darbepoetin) are contraindicated in uncontrolled hypertension and in patients with recent arterial thrombotic events; boxed warning for malignancy-associated anaemia (increased tumour progression risk)
• Allogenic HSCT contraindicated in patients with active uncontrolled infection, severe multi-organ dysfunction, or HLA-incompatible donor without acceptable mismatch protocols
• High-dose systemic corticosteroids for autoimmune haemolytic anaemia require caution in uncontrolled diabetes, active peptic ulcer disease, or severe osteoporosis
Procedure
INTRAVENOUS IRON INFUSION PROTOCOLS:
The cornerstone of moderate-to-severe IDA management where oral supplementation is inadequate or contraindicated. Modern IV iron formulations have largely replaced older high-molecular-weight iron dextran due to superior safety profiles:
• Ferric Carboxymaltose (Ferinject / Injectafer): Single-dose infusion of up to 1,000 mg over 15 minutes; ideal for rapid repletion in a day-care setting. Associated with transient hypophosphataemia in ~30% of patients — monitored with post-infusion phosphate levels.
• Iron Sucrose (Venofer): Administered in divided doses of 100–200 mg over multiple sessions; preferred in chronic kidney disease and paediatric populations due to its established long-term safety record.
• Ferric Derisomaltose (Monoferric): Allows ultra-high single doses (up to 20 mg/kg body weight) in a single 20-minute infusion — the most dose-flexible agent for severe deficiency states.
• Low-Molecular-Weight Iron Dextran (CosmoFer): Used where very large cumulative doses are required (e.g., post-bariatric malabsorption); a test dose is administered due to a marginally higher anaphylaxis risk compared to newer agents.
All infusions are administered in a monitored clinical setting with anaphylaxis management protocols and 30-minute post-infusion observation. A full haemoglobin response is expected within 4–8 weeks; ferritin normalisation by 8–12 weeks.
VITAMIN B12 (COBALAMIN) REPLETION:
• Intramuscular Hydroxocobalamin (Cobalin-H / Neo-Cytamen): The preferred first-line agent for confirmed B12 deficiency and pernicious anaemia. Loading regimen: 1,000 mcg IM daily for 7 days (or alternate days for 2 weeks in neurological involvement), followed by maintenance 1,000 mcg IM every 3 months for life in pernicious anaemia. Hydroxocobalamin is retained in the body longer than cyanocobalamin.
• High-Dose Oral Cyanocobalamin (1,000–2,000 mcg/day): An evidence-based alternative for dietary B12 deficiency without malabsorption (passive absorption through buccal and intestinal mucosa at high doses). Not adequate for pernicious anaemia.
• Methylcobalamin (sublingual or IM): Preferred in patients with MTHFR polymorphism or when neurological protection is a priority, as methylcobalamin is the biologically active form that crosses the blood-brain barrier.
ELECTROPOIESIS-STIMULATING AGENTS (ESAs):
For anaemia of chronic kidney disease (CKD) or chemotherapy-induced anaemia where erythropoietin production is inadequate:
• Epoetin Alfa / Beta (Eprex, NeoRecormon): SC or IV administration, typically 3×/week; titrated to Hb target of 10–12 g/dL (avoiding >12 g/dL due to cardiovascular risk).
• Darbepoetin Alfa (Aranesp): Long-acting ESA (half-life 25× that of epoetin); administered weekly or bi-weekly, significantly improving patient convenience.
• ESAs are always combined with concurrent IV iron supplementation (target ferritin >200 ng/mL, transferrin saturation >20%) to ensure adequate substrate for erythropoiesis.
IMMUNOSUPPRESSIVE THERAPY FOR APLASTIC ANAEMIA / AUTOIMMUNE HAEMOLYTIC ANAEMIA:
• Anti-Thymocyte Globulin (ATG) + Cyclosporine: Standard first-line immunosuppressive protocol for severe aplastic anaemia (SAA) in patients ineligible for HSCT. Horse ATG (hATG, Atgam) demonstrated superiority over rabbit ATG in randomised trials. Response assessed at Day 90–180 by bone marrow biopsy and CBC.
• Eltrombopag (Promacta): A thrombopoietin receptor agonist added to ATG+cyclosporine to stimulate multilineage haematopoiesis; NEJM 2017 data showed complete response rates of 58% with triple therapy vs. 35% with ATG+cyclosporine alone.
• High-dose Corticosteroids (Prednisolone / Methylprednisolone): First-line for warm autoimmune haemolytic anaemia (AIHA); Rituximab (anti-CD20 monoclonal antibody) as second-line for steroid-refractory AIHA.
• Ravulizumab / Eculizumab (terminal complement inhibitors): For paroxysmal nocturnal haemoglobinuria (PNH) — a clonal haematopoietic stem cell disorder causing complement-mediated haemolysis; dramatically reduces haemolysis, transfusion requirements, and thrombosis risk.
ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT):
The only curative option for severe aplastic anaemia, thalassaemia major, and sickle cell disease:
• MSD-HSCT (Matched Sibling Donor): Best outcomes; 5-year overall survival >90% for young patients with SAA.
• MUD-HSCT (Matched Unrelated Donor): For patients lacking matched siblings; outcomes have improved with high-resolution HLA typing and modern GVHD prophylaxis (post-transplant cyclophosphamide, tacrolimus + methotrexate).
• Haploidentical HSCT: Using half-matched family donors (parent, sibling, child); increasingly used in resource-rich centres with T-cell depletion or post-transplant cyclophosphamide protocols — expanding donor availability significantly.
• Reduced-Intensity Conditioning (RIC): For older patients or those with comorbidities who cannot tolerate myeloablative conditioning regimens.
Top haematology centres in India (Tata Memorial Hospital Mumbai, Apollo BMT Chennai, Narayana Health Bangalore) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai) perform HSCT with survival outcomes benchmarked against international registries (CIBMTR/EBMT).
TRANSFUSION MEDICINE & PATIENT BLOOD MANAGEMENT (PBM):
• Leuco-depleted packed red blood cell (PRBC) transfusion for acute severe anaemia (Hb <7 g/dL or Hb <8 g/dL with cardiac symptoms); blood typing and crossmatching performed with extended phenotyping for alloimmunised patients.
• Chelation Therapy (Deferasirox / Deferoxamine): For transfusion-dependent thalassaemia or sickle cell patients with iron overload (serum ferritin >1,000 ng/mL); monitored with T2* MRI cardiac and hepatic iron quantification.
Cost of Anemia: India vs. UAE
The cost of anaemia treatment — spanning from a straightforward IV iron infusion series to complex haematological workup and bone marrow procedures — varies significantly based on the specific intervention, the number of sessions required, and the destination. India offers internationally accredited haematological care at 40–60% lower cost than comparable UAE facilities, making it the preferred destination for budget-conscious international patients without compromising on clinical quality. The UAE, particularly Dubai and Abu Dhabi, offers a premium care environment with luxury hospital amenities, minimal language barriers for Arabic-speaking patients, and direct flight accessibility from across the Middle East, East Africa, and Europe. Both destinations offer transparent, package-based pricing for IV infusion protocols and haematology consultations, with bone marrow biopsy and HSCT priced separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $300 – $8,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $700 – $18,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 weeks before travel):
• Patient submits haematology records, recent CBC, ferritin, B12, and any prior bone marrow reports to GAF Healthcare's medical coordination team.
• GAF Healthcare matches the patient with a senior consultant haematologist at a JCI/NABH-accredited centre (India) or JCI/DHA-accredited centre (UAE).
• Preliminary diagnosis is confirmed or refined via teleconsultation; treatment plan and cost estimate finalised.
• e-Medical Visa application initiated for India (typically approved within 48–72 hours); UAE visit/entry visa arranged for applicable nationalities.
• Accommodation near the treating hospital arranged for patient and attendant (companion stay included in GAF support package).
PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–3):
• Airport pickup by GAF Healthcare's dedicated ground team with language support (Arabic, Russian, French, Swahili, and other major languages available).
• Day 1: Patient registration, haematologist consultation, and baseline blood draw (CBC, ferritin, B12, LFT, RFT, reticulocyte count, haemolysis panel as indicated).
• Day 2–3: Additional diagnostics completed — peripheral blood smear review by haematopathologist, bone marrow aspirate and biopsy (under local anaesthesia, 30-minute procedure) if complex anaemia is suspected; results available within 24–72 hours for routine haematology; cytogenetics/FISH within 7–10 days.
• Imaging studies (abdominal ultrasound for splenomegaly, cardiac ECHO for severe anaemia with cardiopulmonary compromise) performed same day.
PHASE 3 — TREATMENT INITIATION (Days 2–7, outpatient / day-care):
• Iron-Deficiency Anaemia: IV ferric carboxymaltose or ferric derisomaltose infused in a monitored day-care setting over 15–60 minutes; 1–3 sessions over 3–7 days depending on total iron deficit (calculated by Ganzoni formula: Iron deficit [mg] = Body weight [kg] × (Target Hb – Actual Hb) × 2.4 + 500). Vital signs and oxygen saturation monitored throughout and for 30 minutes post-infusion.
• B12 Deficiency Anaemia: IM hydroxocobalamin administered daily for 5–7 days (loading phase); patient and attendant educated on home maintenance injection technique or arrangements made for continuation with local physician on return.
• Aplastic Anaemia / Complex Haematological Workup: Hospital admission for 3–7 days; ATG infusion administered over 12–18 hours daily for 4–5 consecutive days under specialist supervision with intensive monitoring for serum sickness reaction (premedicated with methylprednisolone and antihistamines); cyclosporine and eltrombopag commenced as outpatient continuation.
PHASE 4 — MONITORING & RESPONSE ASSESSMENT (Days 7–14):
• Repeat CBC at Day 7 to assess early reticulocyte response (reticulocyte crisis expected 7–10 days post-IV iron; confirms treatment efficacy).
• Haematologist review consultation; dose adjustment or additional infusion scheduled if required.
• Patients with B12 neurological involvement assessed by neurologist; nerve conduction studies if indicated.
• For aplastic anaemia patients post-ATG: daily CBC monitoring during hospitalisation; discharge planned once the patient is clinically stable with granulocyte counts recovering.
PHASE 5 — PRE-DISCHARGE & FIT-TO-FLY ASSESSMENT:
• Discharge summary, international haematology report, and all laboratory results provided in English (and translated to the patient's language upon request).
• Haematologist certifies fitness to fly — typically 5–7 days post-final IV iron infusion for uncomplicated IDA; 3–4 weeks post-ATG initiation for aplastic anaemia.
• GAF Healthcare arranges airport transfer and provides the patient with a medical travel document summarising diagnosis, treatment received, current medications, and the follow-up monitoring schedule (next CBC at 4 and 8 weeks post-treatment).
• Telemedicine follow-up appointment scheduled at 4 weeks and 12 weeks post-treatment to review Hb, ferritin, and B12 normalisation.
Risks & Considerations
Intravenous iron infusion carries a well-characterised but generally low-risk adverse event profile. Hypersensitivity reactions — ranging from mild flushing, urticaria, and hypotension to rare severe anaphylaxis — occur in approximately 0.5–1.5% of infusions across all modern IV iron formulations; all GAF-affiliated centres maintain full anaphylaxis management protocols (epinephrine, corticosteroids, IV fluids) at chairside. Ferric carboxymaltose specifically is associated with a clinically significant incidence of transient hypophosphataemia (up to 30% of patients), which in rare cases can cause symptomatic osteomalacia with repeated high-dose administration — serum phosphate should be monitored at baseline and 4–6 weeks post-infusion. Iron overload (ferritin >1,000 ng/mL) is a theoretical risk only in patients receiving inappropriately dosed IV iron; monitoring with repeat ferritin at 6–8 weeks post-treatment prevents this complication. Intramuscular B12 injections carry a very low risk of local injection site reactions, and extremely rare anaphylaxis in cobalt-sensitive individuals. Bone marrow biopsy — performed under local anaesthesia from the posterior iliac crest — carries a procedural complication rate below 0.5%, including minor bleeding, haematoma, or superficial wound infection; the procedure is well tolerated and patients are ambulatory within 1–2 hours. For ATG-based immunosuppression in aplastic anaemia, the primary risks include acute serum sickness reaction (fever, rash, arthralgia on Days 7–14, managed with corticosteroids), prolonged neutropenia with associated infection risk (managed with prophylactic antifungals and antibacterials), and a small long-term risk of clonal evolution to myelodysplastic syndrome or PNH (~15% at 10 years). Allogeneic HSCT carries the most significant risk profile, including graft-versus-host disease (GVHD, acute and chronic), transplant-related infections, veno-occlusive disease (VOD/SOS) of the liver, and non-relapse mortality — comprehensively discussed in pre-transplant counselling with each patient. ESA therapy is associated with increased cardiovascular risk (hypertension, thrombosis) when haemoglobin is driven above 12 g/dL; all GAF-affiliated centres adhere to conservative Hb targets per ASH/ASCO guidelines.
Top Hospitals for Anemia
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Tata Memorial Hospital
Mumbai, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Top Doctors for Anemia
Internationally trained specialists in Hematology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Rahul Bhargava
MBBS, MD (General Medicine), DM (Clinical Hematology), Advanced Fellowship in Unrelated and Haploidentical Transplant
Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Rahul Bhargava is a leading Hematologist and BMT specialist currently working at Fortis Memorial Research Institute, Gurugram. With an experience of more than 20 years in Hematology, Pediatric Hemato-Oncology, and Bone Marrow Transplantation, he has performed numerous BMTs with consistently successful outcomes and is widely regarded as one of the most trusted names in this highly specialised field in India. He primarily specialises in haploidentical… Read more
Dr. Vikas Dua
MBBS, MD (Paediatrics), FNB (Paediatric Hematology Oncology), Fellowship in Paediatric Bone Marrow Transplant, Outreach Programme in Paediatric BMT
Pediatric Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Vikas Dua is one of the leading paediatric hemato-oncologists and bone marrow transplant specialists of his generation. He currently serves as Principal Director & Head — Paediatric Haematology, Haemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurgaon. Dr. Dua and his team have performed more than 1,200 transplants, with outcomes among the best in the field of paediatric haematology, oncology and BMT. He is… Read more
Dr. Amita Mahajan
MBBS, MD (Pediatrics), MRCPCH, CCST (Advanced Training in Pediatric Oncology)
Pediatric Hematologist and Oncologist
Indraprastha Apollo Hospital, New Delhi, India
32+ Yearsof experience
Dr. Amita Mahajan is a Senior Consultant in Pediatric Hematology and Oncology at Indraprastha Apollo Hospital, New Delhi, with over 32 years of dedicated clinical experience in childhood blood disorders and cancers. She completed her MBBS and MD in Pediatrics from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by advanced international training: the MRCPCH from the Royal College of Paediatrics and Child Health, London, and… Read more
Dr. Govind Eriat
MBBS, DNB, FRCP, Fellowship in Leukemia/BMT
Hematologist & Hemato-Oncologist
Gleneagles Hospitals, Bengaluru, India
14+ Yearsof experience
Dr. Govind Eriat is a Visiting Consultant in Hematology and Hemato-Oncology at Gleneagles Hospitals, Bengaluru, bringing over 14 years of specialized clinical experience in blood disorders and cancer care. He holds an MBBS degree and has completed his DNB in Internal Medicine, establishing a strong foundation in comprehensive patient care. His international credentials include Fellowship from the Royal College of Physicians (FRCP), United Kingdom, and a… Read more
Dr. K. Karuna Kumar
MD, DNB Clinical Hematology
Hematologist
Yashoda Hospitals, Secunderabad, Hyderabad, India
18+ Yearsof experience
Dr. K. Karuna Kumar is a Clinical Consultant in Hematology with over 18 years of specialised clinical experience. He holds an MD from Nizam's Institute of Medical Sciences (NIMS), Hyderabad, and a DNB in Clinical Hematology from Narayana Hrudayalaya, Bangalore—two of India's most prestigious medical institutions. His training has equipped him with exceptional expertise in both benign and malignant blood disorders, as well as complex transplant procedures.… Read more
Frequently Asked Questions — Anemia
In India, the total cost of anaemia treatment ranges from approximately $300 to $8,000 USD depending on the specific intervention required. A single intravenous iron infusion session (ferric carboxymaltose or iron sucrose) typically costs $150–$400 USD per session, with a 3-session protocol running $400–$900 USD inclusive of haematologist consultation and day-care monitoring. A comprehensive haematology workup including bone marrow biopsy with flow cytometry, cytogenetics, and FISH panel costs $800–$2,500 USD in India. At the complex end, immunosuppressive therapy for aplastic anaemia (ATG + cyclosporine + eltrombopag protocol, inpatient) may cost $4,000–$8,000 USD for the initial hospitalisation course. In the UAE (Dubai/Abu Dhabi), comparable treatments cost 50–60% more: a single IV iron infusion session ranges from $400–$900 USD; a full haematology workup with bone marrow biopsy costs $2,000–$5,500 USD; and aplastic anaemia immunosuppressive therapy inpatient costs $10,000–$18,000 USD. Both destinations include JCI-accredited hospital care; India additionally carries NABH accreditation, while UAE centres hold DHA (Dubai Health Authority) or DOH (Department of Health Abu Dhabi) licensing. All cost estimates from GAF Healthcare are provided as personalised, transparent quotes prior to travel — no hidden facility fees.
The required in-country stay before you are fit for international air travel depends entirely on the type and severity of your anaemia treatment. For uncomplicated iron-deficiency anaemia treated with intravenous iron infusion (1–3 sessions): most patients are fit to fly 5–7 days after their final infusion, once the treating haematologist confirms absence of adverse reaction and initial reticulocyte response is evident. Plan for a total in-country stay of approximately 7–10 days including diagnostic workup and infusion sessions. For vitamin B12 deficiency with neurological involvement requiring intramuscular hydroxocobalamin loading: a minimum 7–10 day stay is recommended to complete the loading regimen and assess early neurological stability; fit-to-fly is typically confirmed at Day 7–10. For complex haematological investigation including bone marrow biopsy: the biopsy itself is a day-procedure; however, awaiting final pathology, cytogenetics, and specialist review requires 10–14 days in-country. For aplastic anaemia patients commencing ATG-based immunosuppressive therapy: a minimum 3–4 week in-country stay is required, as ATG is administered over 4–5 consecutive days in hospital, followed by monitoring for serum sickness, granulocyte count recovery assessment, and initiation of oral maintenance medications (cyclosporine, eltrombopag). Your treating haematologist will issue a formal fit-to-fly certificate, and GAF Healthcare will schedule your departure transfer accordingly to prevent any premature departure risk.
Success rates for anaemia treatment are highly subtype-specific, and understanding realistic outcome benchmarks is critical for informed decision-making. For iron-deficiency anaemia treated with intravenous iron infusion: haemoglobin normalisation (Hb ≥12 g/dL in women, ≥13 g/dL in men) is achieved in 92–97% of patients within 8–12 weeks of a correctly dosed infusion protocol. Serum ferritin replenishment to >50 ng/mL is achieved in >95% of patients. For vitamin B12-deficiency megaloblastic anaemia: haematological response (reticulocyte rise by Day 5–10, Hb normalisation by 6–8 weeks) is seen in virtually 100% of patients with adequate cobalamin repletion; neurological recovery from subacute combined degeneration is partial and slower, with best outcomes when treatment begins within 3–6 months of neurological symptom onset. For autoimmune haemolytic anaemia treated with corticosteroids ± Rituximab: initial remission is achieved in 70–85% of patients; long-term remission in approximately 50–60% after steroid tapering. For severe aplastic anaemia treated with ATG + cyclosporine + eltrombopag: overall haematological response rates of 68–80% are reported in international trials (NEJM 2017 data), with complete response in approximately 58% at 6 months. For young patients (<40 years) undergoing matched sibling donor HSCT for severe aplastic anaemia: 5-year overall survival exceeds 90% at high-volume centres. JCI-accredited centres in India (Tata Memorial, Apollo, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai) report outcomes consistent with international benchmarks published by CIBMTR and EBMT. GAF Healthcare provides patients with centre-specific outcome data and haematologist profiles prior to commitment.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive, personalised non-medical coordination for all international patients undergoing anaemia treatment in India or the UAE, ensuring a stress-free experience from first inquiry to safe return home.
INDIA — VISA & ENTRY: GAF Healthcare facilitates the Indian e-Medical Visa application on the patient's behalf, submitting the haematologist's appointment confirmation letter, GAF's invitation letter, and passport documentation directly to the Indian e-Visa portal. The e-Medical Visa is typically approved within 48–72 hours, permits multiple entries for up to 60 days, and allows one accompanying attendant on a Medical Attendant Visa — processed simultaneously at no additional complexity.
UAE — VISA & ENTRY: Patients from over 50 countries receive visa-free access or a visa-on-arrival for the UAE. For nationalities requiring advance visas, GAF Healthcare's UAE coordination team arranges a 30-day or 60-day medical visit visa via hospital sponsorship, typically processed within 3–5 working days. No in-person embassy visit is required for most patients.
AIRPORT TRANSFERS: Dedicated, air-conditioned vehicle transfers are arranged for the patient and attendant at arrival and departure airports (all major Indian gateway airports — Delhi IGI, Mumbai CSIA, Chennai MAA, Bangalore KIA; Dubai DXB, Abu Dhabi AUH in the UAE). Drivers are briefed on patient medical status and ensure a smooth, unhurried transfer directly to the hospital or accommodation.
ACCOMMODATION: GAF Healthcare partners with hotels and serviced apartments within 1–3 km of all treating hospitals, offering patient-appropriate facilities including accessible rooms, meal services catering to dietary restrictions, and 24-hour reception. Accommodation is arranged for the patient's attendant (or companion) throughout the treatment period. Hospital-adjacent patient lodges (available at major Indian cancer and haematology centres) are also arranged where clinically preferable for close daily monitoring.
DEDICATED PATIENT COORDINATORS & TRANSLATORS: Every patient is assigned a named GAF Healthcare patient coordinator who serves as the single point of contact from Day 1 through post-discharge follow-up. Coordinators speak the patient's language (Arabic, French, Russian, Swahili, Amharic, and other major international languages available) and are available via WhatsApp, telephone, and email. Certified medical interpreters accompany patients to all clinical consultations, diagnostic procedures, and discharge briefings to ensure complete informed consent and treatment comprehension.
POST-TREATMENT FOLLOW-UP: GAF Healthcare schedules structured telemedicine follow-up consultations with the treating haematologist at 4 weeks and 12 weeks post-treatment, with digital transmission of follow-up laboratory results (CBC, ferritin, B12 as applicable) from the patient's local laboratory to the Indian or UAE specialist for remote review and medication adjustment.
Patients Also Explore
Other treatments commonly sought by patients considering Anemia.
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Liver Transplant
Transplant
Lung Transplant
Transplant